Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 93


RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels.

Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ, Smith R, Lessnick SL, Sahasrabudhe S, Stockwell BR.

Nature. 2007 Jun 14;447(7146):864-8.


Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological targets for anti-cancer agents.

Simamura E, Shimada H, Hatta T, Hirai K.

J Bioenerg Biomembr. 2008 Jun;40(3):213-7. doi: 10.1007/s10863-008-9158-6. Review.


Ferroptosis: an iron-dependent form of nonapoptotic cell death.

Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR.

Cell. 2012 May 25;149(5):1060-72. doi: 10.1016/j.cell.2012.03.042.


Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress.

Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N, Jacks T.

Proc Natl Acad Sci U S A. 2011 May 24;108(21):8773-8. doi: 10.1073/pnas.1105941108. Epub 2011 May 9.


Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway.

Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L, Pintzas A.

J Biol Chem. 2005 Jun 17;280(24):22856-67. Epub 2005 Mar 8.


Development of small-molecule probes that selectively kill cells induced to express mutant RAS.

Weïwer M, Bittker JA, Lewis TA, Shimada K, Yang WS, MacPherson L, Dandapani S, Palmer M, Stockwell BR, Schreiber SL, Munoz B.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6. doi: 10.1016/j.bmcl.2011.09.047. Epub 2011 Sep 28.


Protein kinase C delta is required for survival of cells expressing activated p21RAS.

Xia S, Forman LW, Faller DV.

J Biol Chem. 2007 May 4;282(18):13199-210. Epub 2007 Mar 8.


Oncogenic K-Ras requires activation for enhanced activity.

Huang H, Daniluk J, Liu Y, Chu J, Li Z, Ji B, Logsdon CD.

Oncogene. 2014 Jan 23;33(4):532-5. doi: 10.1038/onc.2012.619. Epub 2013 Jan 21.


Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.

Henkhaus RS, Gerner EW, Ignatenko NA.

Biol Chem. 2008 Jun;389(6):757-64. doi: 10.1515/BC.2008.087.


The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression.

Barradas M, Monjas A, Diaz-Meco MT, Serrano M, Moscat J.

EMBO J. 1999 Nov 15;18(22):6362-9.


Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells.

Chi S, Kitanaka C, Noguchi K, Mochizuki T, Nagashima Y, Shirouzu M, Fujita H, Yoshida M, Chen W, Asai A, Himeno M, Yokoyama S, Kuchino Y.

Oncogene. 1999 Apr 1;18(13):2281-90.


Design and synthesis of Pictet-Spengler condensation products that exhibit oncogenic-RAS synthetic lethality and induce non-apoptotic cell death.

Skouta R, Hayano M, Shimada K, Stockwell BR.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5707-13. doi: 10.1016/j.bmcl.2012.06.077. Epub 2012 Jun 30.


Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.

Parikh N, Shuck RL, Nguyen TA, Herron A, Donehower LA.

Mol Cancer Res. 2012 Jun;10(6):845-55. doi: 10.1158/1541-7786.MCR-12-0089. Epub 2012 Apr 24.


Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.

Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, Alberghina L, Stephanopoulos G, Chiaradonna F.

Mol Syst Biol. 2011 Aug 16;7:523. doi: 10.1038/msb.2011.56.


Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents.

Peltonen K, Colis L, Liu H, Jäämaa S, Moore HM, Enbäck J, Laakkonen P, Vaahtokari A, Jones RJ, af Hällström TM, Laiho M.

PLoS One. 2010 Sep 27;5(9):e12996. doi: 10.1371/journal.pone.0012996.


Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.

Eskandarpour M, Kiaii S, Zhu C, Castro J, Sakko AJ, Hansson J.

Int J Cancer. 2005 May 20;115(1):65-73.


Oncogenic K-ras "addiction" and synthetic lethality.

Singh A, Settleman J.

Cell Cycle. 2009 Sep 1;8(17):2676-7. Epub 2009 Sep 23. No abstract available.


Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk